SABS — SAB Biotherapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1833214 ·
Last close
$2.95
Market Cap
$265.76M
52W High
$5.15
52W Low
$2.44
ADV30
682,385
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -25,899,000 -22,300,000 235,644,000 14,438,000 24,723,000
Jun 2026 0 — -23,377,000 -22,491,000 238,210,000 8,267,000 23,425,000
Mar 2026 0 — -19,997,736 -18,868,885 248,470,498 20,519,724 21,222,197
Dec 2025 0 — -15,770,231 -16,860,743 172,809,969 10,502,680 21,315,594

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-53,911,327
Investing CF
$-66,168,155
Financing CF
$105,244,315
CapEx
$-3,912,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.08
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-174,555,000
Inventory
—
Receivables
$1,504,000
ST Investments
$89,611,000
EBIT TTM
$-83,931,421
Pretax Income TTM
$-80,520,628
Interest Exp TTM
$231,499
Analysts
11

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -48,953,363 13,273,683 172,809,969 21,315,594 151,494,375 -44,775,111
Dec 2024 0 -42,910,520 -34,105,309 44,195,469 18,225,893 25,969,576 -34,292,009
Dec 2023 0 -38,075,320 -42,193,786 83,941,253 26,641,812 57,299,441 -25,119,405
Dec 2022 0 -28,917,617 -18,740,804 50,904,927 19,846,785 31,058,142 -23,459,511

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-12,775,159
OpCashFlow TTM
—
Assets (Latest)
$238,210,000
Forward EPS
$-0.95

Peers — same industry

TickerNameMarket CapLastDaily %
TRXB TRex Bio, Inc. $274.46M $10.00 —
ALLO Allogene Therapeutics, Inc. $257.08M $0.74 —
OCGN Ocugen, Inc. $256.75M $0.76 —
EIKN Eikon Therapeutics, Inc. $279.06M $5.15 —
AGEN AGENUS INC $280.98M $6.21 —

News headlines (Yahoo Finance, 1h cache)

SAB Biotherapeutics (SABS) Q3 2026 Earnings Call Transcript
2026-11-06 21:01 · Yahoo
SAB Biotherapeutics Inc (SABS) (Q3 2026) Earnings Call Highlights: FDA Fast-Track Win, Full ...
2026-11-05 23:15 · Yahoo
SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights
2026-11-05 12:30 · Yahoo
SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET
2026-10-29 12:30 · Yahoo
SAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody Platform
2026-10-23 05:02 · Yahoo
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
2026-10-14 12:30 · Yahoo
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
2026-10-13 12:30 · Yahoo
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
2026-09-22 12:30 · Yahoo
SAB BIO to Participate in Upcoming Investor Conferences
2026-09-01 12:30 · Yahoo
SAB Biotherapeutics Q2 Earnings Call Highlights
2026-08-07 12:03 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.